Compare AVDL & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVDL | KALV |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 551.2M |
| IPO Year | 1996 | N/A |
| Metric | AVDL | KALV |
|---|---|---|
| Price | $21.39 | $17.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $18.38 | ★ $26.43 |
| AVG Volume (30 Days) | ★ 2.8M | 1.6M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $248,517,000.00 | $1,426,000.00 |
| Revenue This Year | $65.47 | N/A |
| Revenue Next Year | $30.88 | $204.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 79.88 | N/A |
| 52 Week Low | $6.38 | $7.30 |
| 52 Week High | $23.57 | $17.28 |
| Indicator | AVDL | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 58.68 | 70.46 |
| Support Level | $21.29 | $15.88 |
| Resistance Level | $21.55 | $17.10 |
| Average True Range (ATR) | 0.25 | 1.08 |
| MACD | -0.26 | 0.22 |
| Stochastic Oscillator | 9.50 | 96.52 |
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.